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1. Introduction 
Growth hormone release can be inhibited in vitro 
and in vivo by somatostatin, a tetra decapeptide isolated 
from ovine hypothalamus and characterized by Brazeau 
et al. [ 1 ] . This peptide may act on a secretory step 
occurring in several cell types, since it inhibits insulin 
and glucagon release in vivo [2]. In vitro the release of 
growth hormone can be stimulated by two types of 
secretogogue. The first type, which increases tissue 
cyclic AMP concentrations, includes phosphodiesterase 
inhibitors [3-51 and adenyl cyclase’activators [6-81, 
and the second type includes.the depolarizing agents 
high extracellular K’ and Ba2+ which do not increase 
tissue cyclic AMP [5]. Since somatostatin has been 
shown to alter pituitary cyclic AMP concentrations 
[9] , it might be expected to inhibit growth hormone 
release only in the presence of the first type of secreto- 
gogue. In this report we show that the apparent-Ki for 
somatostatin inhibition of Ba2’-stimulated growth 
hormone release is the same as the apparent-Ki against 
3-isobutyl-I-methylxanthine induced release, indicating 
that the same somatostatin-sensitive step is involved in 
the stimulation of growth hormone release by both 
reagents. This step probably does not involve cyclic 
AMP metabolism, since pituitary cyclic AMP contents 
were not changed on 10 min exposure to Ba2 + with 
or without added somatostatin, although Ba2’-stimu- 
lated growth hormone release was inhibited by soma- 
tostatin over this time. 
2. Materials and methods 
2.1. Tissue incubation procedure 
All incubations were performed in a bicarbonate 
North-Holland Publishing Company - Amsterdam 
buffered salt solution with the ionic composition: Na’ 
143.5 mM, K’ 5.9 mM, Ca2+ 2.3 mM, Mg2+ 0.9 mM, 
Cl- 129.4 mM, H2P04- 1.2 mM and HC03- 
2.5 mM. The medium contained bovine serum albumin 
(1 mg/ml) and glucose (5.0 mM), and was equilibrated 
with O2 : CO2 (95:5). Pituitaries were taken from 
female rats (weight 1 lo-140 g), and hemipituitaries 
weighing l-2.5 mg and free of pars nervosa and pars 
intermedia were incubated in 0.5 ml medium with 
shaking, at 37°C. All pituitaries were preincubated 
for 90 min before the start of experiments. At the end 
of the incubation, the medium was removed and 
stored at - 15°C for growth hormone assay, and the 
tissue was fixed for 90 min at 37’C in sodium phosphate 
(100 mM, pH 7.2) containing 2% glutaraldehyde and 
was then lightly blotted and weighed. 
Ultrastructural observations on the tissue will be 
presented elsewhere. 
2.2. Measurement of rat growth hormone 
Rat growth hormone reference standard (Rat 
GHRP-l), rat growth hormone for iodination (Rat GH- 
11-2) and anti-rat growth hormone serum (monkey, 
A-rat GHS-2) were obtained from The Hormone 
Distribution Officer, N.I.H. Bethesda. Growth 
hormone was iodinated using chloramine-T [ lo] . The 
growth hormone assay was performed in 200 ~1 barbi- 
tone (50 mM, pH 8.4) containing sodium azide (25 
mM) and bovine serum albumin (1 mg/ml). Free labelled- 
growth hormone was absorbed onto charcoal in the 
presence of dextran and albumin [ 111, and removed by 
centrifugation: supernatant antibody-bound hormone 
was determined using a Packard 3002 y counter. 
171 
Volume 46. number 1 FEBS LETTERS September 1974 
2.3. Tissue extraction and cyclic AMP assay 
When tissue cyclic AMP concentrations were 
measured, media were removed after a 10 min incuba- 
tion, and 0.5 ml ice-cold TCA (5%) added to the tissue 
which was then homogenized. Protein was removed by 
centrifugation, redissolved in 0.5 N NaOH containing 
5% sodium dodecyl sulphate and the concentration of 
protein determined using the Lowry procedure [ 121. 
TCA supernatants were neutralized with Tris hydroxide 
(3.5 M), purified on Dowex 5OWX8 [13] and freeze- 
dried in two aliquots. The lyophilate was reconstituted 
in 20 ~1 Hz 0 and the cyclic AMP concentration deter- 
mined by a binding-protein assay [ 141 . 
3. Results 
Growth hormone release was increased by 3-isobutyl- 
I-methylxanthine, the maximum stimulation being 
seen at 0.5 mM (fig. la). Addition of somatostatin 
(2 pg/ml) completely prevented this increase in release 
at all 3-isobutyl-l-methylxanthine concentrations 
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tested. In the presence of 0.5 mM 3-isobutyl-l- 
methylxanthine, significant inhibition of release was 
observed in the presence of 2 ng/ml somatostatin, and 
half maximal inhibition at about 20 ng/ml (fig. lb). 
Growth hormone release was increased by BaCl 2 
in the concentration range 0 to 8.8 mM, although this 
did not give maximum rates of release (fig. 2a). In the 
presence of 4.6 mM Ba2 +, growth hormone release was 
half maximally inhibited by 20 ng/ml somatostatin 
(fig. 2b). Addition of somatostatin at 2 pg/ml completely 
inhibited stimulation of growth hormone release by low 
concentrations of Ba2 + , but inhibition was partially 
overcome by increasing the BaC12 concentration to 
8.8 mM (fig. 2a). 
After 10 min incubation in the presence of 3- 
isobutyl-1-methylxanthine, pituitary cyclic AMP con- 
tents were increased 7.3 fold; 4.6 mM Ba2 + had no 
effect on cyclic AMP content (table 1). By contrast, 
growth hormone release was not significantly increased 
by 3-isobutyl-1 -methylxanthine after 10 min, but was 
increased 3.6 fold by 4.6 mM Ba2+ and somatostatin 
inhibited this increase. Somatostatin decreased the 
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Fig. 1. Effect of somatostatin on 3-isobutyl-1-methylxanthine induced growth hormone release. Fig. la shows growth hormone 
release during 60 min in absence (m, n = 12) or presence (0, n = 4) of somatostain (2 pg/ml). Fig. lb shows release during 30 min 
in absence (m, n = 8) or presence (0, n = 8) of 0.5 mM 3-isobutyl-1-methylxanthine. Vertical bars are standard error of mean. 
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Fig. 2. Effect of somatostatin on Ba2 l . induced growth hormone release. Fig. 2a shows growth hormone release during 30 min incu- 
bation in the absence (0, n = 8) or presence (m, n = 8) of somatostatin (2 rg/ml). Fig. 2b shows growth hormone release during 60 
min in absence (q n = 8) or presence (m, n = 8) of 4.6 mM BaCl, Vertical bars are standard error of mean. 
Table 1 
Effect of somatostatin on growth hormone release and cyclic AMP content of pituitaries incubated for 10 min 
GH release 
Olg/mg protein) 
No somatostatin 
O.rg/mg protein) 
+ somatostatin (%) 
Cyclic AMP content 
(pmoles/mg (pmoles/mg 
protein) No protein) + 
somatostatin somatostatin 
(%) 
Control 
3-isobutyl-l- 
methylxanthine 
Ba’ + 
2.3650.57 1.52to.19 80+15 13.4+ 0.46 12.0+ 1.27 89+8 
3.07tO.27 2.1720.39 76r15 98.0* 15.0a 69.3tll.O 7125b 
8.41~1.63~ 3.11*0.50a 48*13b 11.0* 0.9 12.4r 0.6 115k6 
Significance levels: a) P < 0.01 for difference from appropriate control without somatostatin; b) p < 0.01 for difference from 100%. 
Pituitaries were preincubated for 90 min and incubated for 10 min in 0.5 ml medium containing glucose (5 mM) and albumin 
(1 mg/ml). Concentrations of other reagents were: somatostatin 2 rg/ml; BaCl, ,4.6 mM; 3-isobutyl-1-methylxanthine, 0.5 mM. 
Six half pituitaries were incubated without somatostatin and the 6 paired halves incubated under the same conditions but with 
somatostatin. Thus growth hormone release (or cyclic AMP content) in the presence of somatostatin is also expressed as % of the 
release (or cyclic AMP content) of the paired half pituitary incubated in the absence of somatostatin. Data is mean * standard er- 
ror. 
173 
Volume 46, number 1 FEBS LETTERS September 1974 
pituitary cyclic AMP content by 30% in the presence 
of 3-isobutyl-1-methylxanthine; the difference became 
significant when expressed as % of paired control to 
eliminate interanimal differences in the number of 
somatotrophs. Somatostatin did not change cyclic 
AMP concentrations in control tissue, and may have 
slightly increased them in the presence of BaC 1 2 . 
4. Discussion 
These results show that in the rat hemipituitary as 
in the heifer pituitary slice [S] , Ba’ + can increase 
growth hormone release without changing the intra- 
cellular concentration of cyclic AMP. Thus an increase 
in cyclic AMP is not essential for stimulation of either 
ox or rat growth hormone release. The rise in pituitary 
cyclic AMP appeared to precede the rise in hormone 
release, perhaps because it is indirectly linked to the 
secretory pathway. Thus BaClz increased hormone 
release during a 10 min incubation, whereas 10 min 
exposure to 3-isobutyl-1-methylxanthine did not signi- 
ficantly increase growth hormone release despite 
increased cyclic AMP concentrations. A similar delay 
has been observed following prostaglandin Ez [8]. 
The observation that the apparent-Ki for somatostatin 
inhibition of release stimulated by both secretogogues 
was 20 nm suggests that somatostatin affects the same 
secretory step in the presence of both stimuli. Soma- 
tostatin could inhibit this step by decreasing the con- 
centration of cyclic AMP, since this might inhibit Ba2’- 
induced growth hormone release : the converse effect, 
increased Ba2’-induced release from pituitary slices 
containing increased cyclic AMP concentrations, has 
been reported [S] . The data presented here do not 
support this explanation. Somatostatin did not signifi- 
cantly decrease cyclic AMP concentrations in control 
pituitaries and may even have increased them in the 
presence of BaC12. An alternative explanation would 
be that somatostatin alters the distribution of Ca2 + in 
the tissue or its interaction with the secretory pathway. 
Our observation that increasing the BaCl2 concentration 
in the presence of somatostatin was able to stimulate 
growth hormone release could suggest some competition 
between the peptide and divalent cation. 
It is therefore of interest that somatostatin decreased 
pituitary cyclic AMP content in the presence of 3- 
isobutyl-I-methylxanthine. In the female pituitaries 
used in these studies, 33 + 2.5% of all cells are soma- 
totrophs (based on 2186 cells in sections from 12 
pituitaries). Thus a fall of 29 f 4.6% in pituitary cyclic 
AMP content could represent virtually complete inhi- 
bition of cyclic AMP accumulation in somatotrophs, 
either through inhibition of cyclic AMP production or 
through reversal of 3-isobutyl-l-methylxanthine 
action. It is not known how far a change in intracellular 
cyclic AMP concentration could be explained by the 
postulated effect of somatostatin on divalent cation 
metabolism. 
Acknowledgements 
We are grateful to Dr R. Guillemin for his generous 
gift of linear somatostatin, and to Dr W. Malaisse for 
interest and advice. The work was supported by grant 
No 3.8080.72 from the Fonds National Suisse de la 
Recherche Scientifique. 
References 
111 
121 
[31 
[41 
151 
[61 
[71 
[81 
[91 
[lOI 
1111 
1121 
[I31 
[I41 
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., 
Rivier, .I. and Guillemin, R. (1973) Science 179, 77-79. 
Koerker, D. J., Ruth, W., Chideckel, E., Palmer, J., 
Goodner, C. J., Ensinck, J. and Gale, C. C. (1974) Science 
184,482-484. 
Steiner, A. L., Peake, G. T., Utiger, R. D., Karl, I. E. and 
Kipnis, D. M. (1970) Endocrinology 86, 1354-1360. 
Peake, G. T., Steiner, A. L. and Daughaday, W. H. (1972) 
Endocrinology 90, 212-216. 
Schofield, J. G. and McPherson, M. A. (1974) Biochem. 
J. In press. 
McLeod, R. M. and Lehmeyer, J. E. (1970) Proc. Natl. 
Acad. Sci. U.S. 67, 1172-1179. 
Deery, D. J. and Howell, S. L. (1973) Biochim. Biophys. 
Acta 329, 17-22. 
Cooper, R. H., McPherson, M. and Schofield, J. G. (1972) 
Biochem. J. 127, 143-154. 
Borgeat, P., Labrice, F., Drovin, J., Belanger, A., Immer, 
H., Sestanj, K., Nelson, V., Gotz, M., Shally, A. V., 
Coy, D. H. and Coy, E. J. (1974) Biochem. Biophys. 
Res. Comm. 56,1052-1059. 
Greenwood, F. C., Hunter, W. M. and Glover, J. S. 
(1963) Biochem. J. 89, 114-123. 
Gottlieb, C., Lan, K. S., Wasserman, L. R. and Herbert, V. 
(1965) Blood 25, 875-881. 
Lowry, 0. H., Rosebrough, N. J., Farr, A. L. and Randall, 
R. J. (1951) J. Biol. Chem. 193, 265-275. 
Krishna, G., Weiss, B. and Brodie, B. B. (1968) J. 
Pharmacol. Exptl. Therap. 163, 379-385. 
Brown, B. L., Albano, J. D. M., Ekins, R. P. and Sherzi, 
A. M. (1970) Biochem. J. 121, 561-562. 
174 
